Page 19 - 2019 Annual Report
P. 19

A. Good, MD, PhD (fig. 4). Dr. Good pioneered work on the role of the thymus in immunity and treated a patient with severe immune deficiency with the first successful human bone marrow transplant between persons who were not identical twins. Dr. Cooper, a 2019 Albert Lasker Awardee, was to discover that there are two distinct types of lymphocytes, T and B cells. As the study of lymphocytes advanced, a third type—the natural killer cells—so named because of their role in killing tumor cells,―was identified.
Drs. Warlick and Miller are members of the University’s Masonic Cancer Center, a collaborative research environment that includes some of the world’s top scientists in the treatment, genetics, immunology, biology, and epidemiology of cancer.
Lowering the Risk
In a paper recently published in the Journal of Clinical Oncology, authors Lucie Turcotte, MD, MPH, assistant professor, and Joseph Neglia, MD, MPH, department head and professor in the Department of Pediatrics, looked at childhood cancer survivors treated with different classes of chemotherapy.
Drs. Turcotte, Neglia, and colleagues found that childhood cancer survivors who were treated with chemotherapy only, particularly higher cumulative doses of platinum and alkylating agents, face an increased risk of secondary cancer. Linear dose responses were seen between alkylating agents and subsequent malignant neoplasm rates, as well as between anthracyclines and breast cancer rates. They hypothesized that limiting cumulative doses and possibly using alternate chemotherapy could reduce secondary cancer risk.
  Duluth campus welcomes largest class of Native American students. In the class of 2023, 12 of 65 students identify as Native American/American Indian/Alaskan Native.

   17   18   19   20   21